



Proteomics International

LABORATORIES LTD

ASX Release

26 July 2019

ASX code: PIQ

Proteomics International secures new contracts for pharmacokinetic analysis

- **Proteomics International expands partnership with Linear Clinical Research, securing two new analytical services contracts with a combined value of \$418,000**
- **Contracts to perform pharmacokinetic testing of novel autoimmune disease drugs further validate Proteomics International's analytical services capabilities**
- **Proteomics International's analytical services experience continued revenue growth, supporting the development and commercialisation of the Company's portfolio of pioneering diagnostics**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International, the Company) (ASX: PIQ) has secured two new contracts to conduct pharmacokinetic (PK) analyses.

The analytical testing contracts, with a combined value of \$418,000, form part of Proteomics International's on-going partnership with Linear Clinical Research for pharmacokinetic testing for clinical trials. The phase I clinical studies will examine the safety performance of novel autoimmune disease drugs for two China based pharmaceutical companies, with the studies to be undertaken over the next 3-10 months.

Proteomics International continues to grow its demanded, analytical services business, whilst concurrently commercialising its ground-breaking predictive test for diabetic kidney disease, PromarkerD. The Company continues to develop existing regional PromarkerD licensing agreements, whilst actively pursuing newly identified opportunities.

Proteomics International Managing Director, Dr Richard Lipscombe said, "we're excited by the continued development of the Company's commercial partnership with Linear Clinical Research [ASX: 15 Nov 2016]. The contracts further validate Proteomics International's pharmacokinetic testing capabilities, and highlight the growth potential of our analytical services business. These specialist services will continue to present opportunities to generate valuable revenues, which help offset the cost of developing and commercialising the Company's portfolio of pioneering diagnostics."

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD. The company offsets the cash burn from R&D and

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
[Corporate Advisor & Investor Relations]
Adelaide Equity Partners
T: +61 8 8232 8800
E: dvandissel@adelaideequity.com.au